

AstraZeneca Docket No. 100819-1P US

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Application of: **Peter Bernstein et al.**  
International Application Number: **PCT/SE2003/001329**  
International Filing Date: **August 26, 2003**  
For: **NAPHTHAMIDE DERIVATIVES AND THEIR USE**

Group Art Unit: **Not yet allocated**  
Examiner: **Not yet allocated**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit herewith a list of patents and publications which they believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.


In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

The references listed on the attached Form PTO/SB/08a and PTO/SB/08b were cited by the Examiner in the International Search Report.

This Information Disclosure Statement is being filed within three months of the filing of the application. Accordingly, no fee is required for consideration of the references filed herewith.

Respectfully submitted,

Dated: February 23, 2005

By:   
Kenneth F. Mitchell, Ph.D.  
Attorney for Applicants  
Reg. No. 42,007  
Telephone: 302/886-7466

DT13 PCT/PTO 23 FEB 2005

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**Complete if Known**

(Use as many sheets as necessary)

1

○

1

IA No. PCT/SE2003/001329

Intl. Filing Date 8/26/2003

Peter Bernstein

100819-1P US

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	1	WO	9413639	A1	06/23/1994	Merck Sharp & Dohme	Cl. 1, Cl 10, ln 16-17, ln 31-33, pg 16, ln 31-pg 18, ln 12	
	2	WO	0025786	A1	05/11/2000	Merck & Co.	claims 2-9, pg 52, lines 5-17	
	3	WO	0002859	A1	01/20/2000	Zeneca Ltd.	the claims	
	4	WO	02051807	A1	07/04/2002	AstraZeneca AB	the claims, pg 16, lines 19-20	
	5	WO	0020389	A1	04/13/2000	Zeneca Ltd.	the claims	

**Considered**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Substitute for form 1449B/PTO

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	IA No. PCT/SE2003/001329
Filing Date	Intl. Filing Date 8/26/2003
First Named Inventor	Peter Bernstein
Art Unit	
Examiner Name	
Attorney Docket Number	100819-1P US

Sheet	1	of	1
-------	---	----	---

Examiner  
Initials\*Cite  
No.<sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

 $\tau^2$ 

THOMAS RYCKMANS ET AL., "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants," *Biorganic & Medicinal Chemistry Letters*, Vol. 12 (No. 2), p. 261-264, (January 22, 2002).

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*